{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:59:27Z","timestamp":1790452767946,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinthera.2026.09.005","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:32:45Z","timestamp":1790451165000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety Challenges and Emerging Solutions in Regenerative Medicine: Tissue Engineering, Cell Therapy, and Gene Therapy"],"prefix":"10.1016","author":[{"given":"Seema","family":"Kumbhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.09.005_bib0001","unstructured":"FDA. Regenerative Medicine Advanced Therapy Designation. Updated November 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/regenerative-medicine-advanced-therapy-designation."},{"key":"10.1016\/j.clinthera.2026.09.005_bib0002","unstructured":"Gilead\/Kite Pharma. Yescarta Delivers Consistent Safety, Efficacy, and Quality of Life Benefits. ASH 2025, https:\/\/www.gilead.com\/news."},{"key":"10.1016\/j.clinthera.2026.09.005_bib0003","unstructured":"Novartis AG. Five-Year Kymriah Data Show Durable Remission. Updated 2025. https:\/\/www.novartis.com\/news\/media-releases\/novartis-five-year-kymriah-data-show-durable-remission-and-long-term-survival-maintained-children-and-young-adults-advanced-b-cell-all."},{"key":"10.1016\/j.clinthera.2026.09.005_bib0004","unstructured":"Humacyte Inc. FDA approval of acellular tissue engineered vessel."},{"key":"10.1016\/j.clinthera.2026.09.005_bib0005","series-title":"FDA Publishes New Draft Guidance on Regenerative Medicine Therapies","year":"2025"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0006","unstructured":"FDA CBER. Human Cells, Tissues, and Cellular and Tissue-Based Products Regulatory Framework. 2025. https:\/\/www.raps.org\/resource\/fda-industry-look-to-revisit-regulatory-framework.html"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0007","unstructured":"Cellares. Automated manufacturing network and cell shuttle platform."},{"key":"10.1016\/j.clinthera.2026.09.005_bib0008","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0009","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0010","article-title":"CAR-T-cell-neurotoxicity in the hematologic cell central nervous system: is it still a concern?","volume":"14","author":"Velasco","year":"2023","journal-title":"Frontier Neurol"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0011","unstructured":"CGT Live. Top FDA Gene and Cell Therapy News: 2025 Year-End Recap. December 2025. https:\/\/www.cgtlive.com\/view\/top-fda-gene-cell-therapy-news-2025-year-end-recap"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0012","series-title":"Programmable T-cell Engineering Platform","year":"2026"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0013","unstructured":"Arcellx Inc. Next-generation BCMA CAR-T safety data."},{"key":"10.1016\/j.clinthera.2026.09.005_bib0014","unstructured":"Janssen Biotech. Carvykti Prescribing Information. 2025. https:\/\/www.carvyktihcp.com\/?gclsrc=aw.ds&gad_source=1&gad_campaignid=16486675898&gbraid=0AAAAAoJDeRy7JGZbEUldGRby7Sk5TBwwX&gclid=Cj0KCQjw8c3VBhCsARIsAA_xJ90bir4ZmP0bl7yrv0XC320miGcINz5hSTziEL9SdYAJYVDjuIBwxxMaAhKIEALw_wcB#"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0015","unstructured":"Bristol Myers Squibb. Breyanzi Clinical Safety Profile. 2025. https:\/\/www.breyanzihcp.com\/?cid=sem_3026151&gclsrc=aw.ds&gad_source=1&gad_campaignid=22038204604&gbraid=0AAAAAq0LmbRiHelObeUpYNrtFdrtbO0jj&gclid=Cj0KCQjw8c3VBhCsARIsAA_xJ92w-dJCM0SIne0QXPlUcyOz58xGk2evnhnIBXyYABsOrsvZtTSHMzgaAvydEALw_wcB"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0016","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0017","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0018","unstructured":"Lyfgenia Prescribing Information FDA., Boxed Warning. 2024. https:\/\/www.lyfgenia.com\/what-is-lyfgenia?utm_source=google&utm_medium=cpc&utm_campaign={campaign}&utm_content=184046327496&utm_term=lyfgenia&gad_source=1&gad_campaignid=22874718461&gbraid=0AAAABA9yl2wIp9XIICQS1h7qsRB0jS3qd&gclid=Cj0KCQjw8c3VBhCsARIsAA_xJ92MbXoKprnpyoW3X2xrCh_jWpaQ2AXFY3t6CPi4cqtDCj5-4iI29kIaAsLxEALw_wcB."},{"key":"10.1016\/j.clinthera.2026.09.005_bib0019","unstructured":"Bluebird Bio. Skysona safety update."},{"key":"10.1016\/j.clinthera.2026.09.005_bib0020","unstructured":"Beam Therapeutics. BEAM-101 Base Editing Program Update. 2025. https:\/\/beamtx.com\/wp-content\/uploads\/2025\/06\/BEAM-101-EHA_Final_22May2025.pdf"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0021","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0022","unstructured":"Novartis Gene Therapies. Zolgensma prescribing information."},{"key":"10.1016\/j.clinthera.2026.09.005_bib0023","unstructured":"Sarepta Therapeutics. Elevidys safety labeling update."},{"key":"10.1016\/j.clinthera.2026.09.005_bib0025","doi-asserted-by":"crossref","unstructured":"Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149\u2013157.","DOI":"10.1038\/s41586-019-1711-4"},{"key":"10.1016\/j.clinthera.2026.09.005_bib0026","unstructured":"Cellistic, Van Damme, Astrid, Genetic Engineering and Biotech News, April 2026."},{"key":"10.1016\/j.clinthera.2026.09.005_bib0027","unstructured":"Gangurde, R, Winitsky, S., Parexel. Published on: July 31, 2024."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826003450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826003450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:32:52Z","timestamp":1790451172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826003450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["S0149291826003450"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.09.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety Challenges and Emerging Solutions in Regenerative Medicine: Tissue Engineering, Cell Therapy, and Gene Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}